Europe Oral Solid Dosage Cdmo Market Size & Outlook
Europe oral solid dosage cdmo market, 2018-2030 (US$M)
Related Markets
Europe oral solid dosage cdmo market highlights
- The Europe oral solid dosage cdmo market generated a revenue of USD 9,223.7 million in 2023.
- The market is expected to grow at a CAGR of 6.5% from 2024 to 2030.
- In terms of segment, tablets was the largest revenue generating product in 2023.
- Capsules is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 9,223.7 million |
| Market revenue in 2030 | USD 14,319.8 million |
| Growth rate | 6.5% (CAGR from 2023 to 2030) |
| Largest segment | Tablets |
| Fastest growing segment | Capsules |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tablets, Capsules, Powders, Granules |
| Key market players worldwide | Catalent Inc, Lonza Group Ltd, Kuehne + Nagel International AG, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Siegfried Holding AG, AbbVie Inc, Chemical Works of Gedeon Richter PLC, Jubilant Pharmova, Piramal Pharma Solutions, Recipharm, CordenPharma |
Other key industry trends
- In terms of revenue, Europe region accounted for 22.4% of the global oral solid dosage cdmo market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 23,839.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oral Solid Dosage CDMO Market Scope
Oral Solid Dosage CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe oral solid dosage cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oral solid dosage cdmo market will help companies and investors design strategic landscapes.
Tablets was the largest segment with a revenue share of 31.87% in 2023. Horizon Databook has segmented the Europe oral solid dosage cdmo market based on tablets, capsules, powders, granules covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the third-largest share of the global oral solid dosage CDMO market in 2023, owing to the presence of reputed pharmaceutical companies in this region. Europe has a robust pharmaceutical sector with numerous drug discoveries, development, and manufacturing companies.
These CDMOs are investing in upgrading existing capabilities to meet the rising demand, divesting their business segments to increase focus on one most crucial businesses. as well as investing in building new facilities to expand their market reach within the region.
For instance, in November 2023, Cambrex divested its Drug Product Business Unit to Noramco. This business involves product development, clinical and commercial manufacturing, and packaging, with facilities in Canada & the U.S.
Reasons to subscribe to Europe oral solid dosage cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe oral solid dosage cdmo market databook
-
Our clientele includes a mix of oral solid dosage cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe oral solid dosage cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe oral solid dosage cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe oral solid dosage cdmo market size, by country, 2018-2030 (US$M)
Europe Oral Solid Dosage CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
